IL225881B - Delayed release formulation of a non-steroidal anti-inflammatory drug - Google Patents

Delayed release formulation of a non-steroidal anti-inflammatory drug

Info

Publication number
IL225881B
IL225881B IL225881A IL22588113A IL225881B IL 225881 B IL225881 B IL 225881B IL 225881 A IL225881 A IL 225881A IL 22588113 A IL22588113 A IL 22588113A IL 225881 B IL225881 B IL 225881B
Authority
IL
Israel
Prior art keywords
sustained release
release formulation
steroidal anti
inflammatory drug
inflammatory
Prior art date
Application number
IL225881A
Other languages
English (en)
Hebrew (he)
Other versions
IL225881A0 (en
Original Assignee
Pacira Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacira Pharmaceuticals Inc filed Critical Pacira Pharmaceuticals Inc
Publication of IL225881A0 publication Critical patent/IL225881A0/en
Publication of IL225881B publication Critical patent/IL225881B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277Preparation processes; Proliposomes
    • A61K9/1278Post-loading, e.g. by ion or pH gradient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL225881A 2010-10-28 2013-04-22 Delayed release formulation of a non-steroidal anti-inflammatory drug IL225881B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40787210P 2010-10-28 2010-10-28
PCT/US2011/058169 WO2012058483A1 (en) 2010-10-28 2011-10-27 A sustained release formulation of a non-steroidal anti-inflammatory drug

Publications (2)

Publication Number Publication Date
IL225881A0 IL225881A0 (en) 2013-06-27
IL225881B true IL225881B (en) 2018-06-28

Family

ID=45994412

Family Applications (1)

Application Number Title Priority Date Filing Date
IL225881A IL225881B (en) 2010-10-28 2013-04-22 Delayed release formulation of a non-steroidal anti-inflammatory drug

Country Status (7)

Country Link
US (6) US10610486B2 (enExample)
EP (1) EP2632553B1 (enExample)
JP (3) JP6194248B2 (enExample)
CN (1) CN103260702B (enExample)
ES (1) ES2770575T3 (enExample)
IL (1) IL225881B (enExample)
WO (1) WO2012058483A1 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012058483A1 (en) 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
JP5813011B2 (ja) * 2010-12-27 2015-11-17 テルモ株式会社 リポソーム組成物およびその製造方法
US20130337051A1 (en) * 2011-03-01 2013-12-19 To-Bbb Holding B.V. Advanced active liposomal loading of poorly water-soluble substances
EP2846773A4 (en) 2012-05-10 2015-12-30 Painreform Ltd DEPOT FORMULATIONS OF A LOCAL ANESTHETICS AND METHOD FOR THE MANUFACTURE THEREOF
HUE062466T2 (hu) 2012-07-05 2023-11-28 Taiwan Liposome Co Ltd Eljárások arthritis kezelésére
CN106659683A (zh) * 2014-01-14 2017-05-10 约翰斯·霍普金斯大学 包封修饰的环糊精复合物的脂质体组合物及其应用
GB2541835B (en) * 2015-01-21 2018-09-12 Pacira Pharmaceuticals Inc Multivesicular liposome formulations of tranexamic acid
GB201505527D0 (en) 2015-03-31 2015-05-13 Jmedtech Pte Ltd Composition
EP3317448B1 (en) 2015-06-30 2021-09-08 Tela Bio, Inc. Corner-lock stitch patterns
US10426587B2 (en) 2015-07-21 2019-10-01 Tela Bio, Inc. Compliance control stitching in substrate materials
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3448308B1 (en) 2016-04-26 2024-08-14 Tela Bio, Inc. Hernia repair grafts having anti-adhesion barriers
CN106491533B (zh) * 2016-11-11 2019-08-20 江苏九旭药业有限公司 一种稳定的氟比洛芬酯组合物及制备方法
CN109983013A (zh) * 2016-11-18 2019-07-05 帕西拉制药有限公司 美洛昔康锌复合物微粒多囊脂质体制剂及其制备方法
KR102069670B1 (ko) * 2017-03-02 2020-01-23 단디바이오사이언스 주식회사 면역활성물질을 포함하는 다중도메인캡슐, 이의 제조방법, 및 이를 포함하는 면역조절 조성물
WO2019071245A1 (en) 2017-10-06 2019-04-11 Foundry Therapeutics, Inc. IMPLANTABLE DEPOSITS FOR REGULATED RELEASE OF ANALGESICS TO TREAT POSTHOPERATIVE PAIN ASSOCIATED WITH ORTHOPEDIC SURGERY, AND RELATED DEVICES, SYSTEMS, AND METHODS
EP3737433A1 (en) 2018-01-08 2020-11-18 Foundry Therapeutics, Inc. Devices, systems, and methods for treating intraluminal cancer via controlled delivery of therapeutic agents
US11590262B2 (en) 2018-03-09 2023-02-28 Tela Bio, Inc. Surgical repair graft
CA3099890A1 (en) 2018-05-12 2019-11-21 Foundry Therapeutics, Inc. Implantable polymer depots for the controlled release of therapeutic agents
US12303619B2 (en) 2018-08-28 2025-05-20 Foundry Therapeutics, Inc. Polymer implants
BR112021003256A2 (pt) * 2018-09-14 2021-05-18 Pharmosa Biopharm Inc. composição farmacêutica, método para tratar uma doença respiratória e método para reduzir o efeito colateral de uma droga de ácido fraco
JP7229012B2 (ja) * 2018-12-25 2023-02-27 小林製薬株式会社 内服用医薬組成物
WO2020185688A1 (en) 2019-03-08 2020-09-17 Tela Bio, Inc. Textured medical textiles
CN114732786A (zh) * 2021-01-07 2022-07-12 广州曼翔医药有限公司 一种注射用氯诺昔康脂质体
US11357727B1 (en) 2021-01-22 2022-06-14 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11278494B1 (en) 2021-01-22 2022-03-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12151024B2 (en) 2021-01-22 2024-11-26 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US11033495B1 (en) 2021-01-22 2021-06-15 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
CN113509440B (zh) * 2021-03-26 2022-08-30 中国药科大学 一种高包封率酮咯酸多囊脂质体制备及提高其稳定性方法
CN113616597A (zh) * 2021-08-02 2021-11-09 上海交通大学 一种美洛昔康的注射剂及其制备方法和用途
WO2023064464A1 (en) 2021-10-14 2023-04-20 Pacira Pharmaceuticals, Inc. Bupivacaine multivesicular liposome formulations and uses thereof
CN116077435B (zh) * 2023-04-07 2023-06-02 山东恒邦中科生物工程有限公司 一种兽用高浓度美洛昔康注射剂的制备方法
US12251472B1 (en) 2024-05-20 2025-03-18 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12280149B1 (en) 2024-05-20 2025-04-22 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes
US12156940B1 (en) 2024-05-20 2024-12-03 Pacira Pharmaceuticals, Inc. Manufacturing of bupivacaine multivesicular liposomes

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3547119A (en) 1967-12-08 1970-12-15 Baxter Laboratories Inc Catheter assembly
US4311137A (en) 1980-04-30 1982-01-19 Sherwood Medical Industries Inc. Infusion device
US4612370A (en) 1982-04-02 1986-09-16 The Regents Of The University Of California Lipid-saccharide reaction products
US4531937A (en) 1983-01-24 1985-07-30 Pacesetter Systems, Inc. Introducer catheter apparatus and method of use
US4565696A (en) 1983-08-03 1986-01-21 The Regents Of The University Of California Production of immunogens by antigen conjugation to liposomes
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5230899A (en) 1985-08-07 1993-07-27 Smithkline Beecham Corporation Methods and compositions for making liposomes
US4755173A (en) 1986-02-25 1988-07-05 Pacesetter Infusion, Ltd. Soft cannula subcutaneous injection set
GB8607717D0 (en) 1986-03-27 1986-04-30 Unilever Plc Hydratable powders
JPH01501622A (ja) * 1986-06-12 1989-06-08 ザ リポソーム カンパニー,インコーポレイテッド リポソームにカプセル包囲された非ステロイド性抗炎症薬を用いる方法および組成物
US6759057B1 (en) * 1986-06-12 2004-07-06 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
WO1987007506A1 (en) 1986-06-12 1987-12-17 The Liposome Company, Inc. Methods and compositions using liposome-encapsulated non-steroidal anti-inflammatory drugs
US5204112A (en) 1986-06-16 1993-04-20 The Liposome Company, Inc. Induction of asymmetry in vesicles
US4877619A (en) 1986-08-25 1989-10-31 Vestar, Inc. Liposomal vesicles for intraperitoneal administration of therapeutic agents
GB8704171D0 (en) * 1987-02-23 1987-04-01 Clayton Found Res Multivesicular liposomes
US5723147A (en) 1987-02-23 1998-03-03 Depotech Corporation Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
US5576017A (en) 1988-05-30 1996-11-19 Depotech Corporation Heterovesicular liposomes
AU664359B2 (en) * 1990-12-03 1995-11-16 Nexstar Pharmaceuticals, Inc. Prevention of synovial adhesions
US5230800A (en) 1992-02-20 1993-07-27 Minnesota Mining And Manufacturing Company Scrim inserted electrostatic fibrous filter web
US5545143A (en) 1993-01-21 1996-08-13 T. S. I. Medical Device for subcutaneous medication delivery
US5759573A (en) 1993-04-22 1998-06-02 Depotech Corporation Cyclodextrin liposomes encapsulating pharmacologic compounds and methods for their use
US5766627A (en) 1993-11-16 1998-06-16 Depotech Multivescular liposomes with controlled release of encapsulated biologically active substances
RO116341B1 (ro) * 1993-11-16 2001-01-30 Depotech Corp La Jolia Lipozom multivezicular si procedeu de obtinere a acestuia
US5993850A (en) 1994-09-13 1999-11-30 Skyepharma Inc. Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
US6193963B1 (en) 1996-10-17 2001-02-27 The Regents Of The University Of California Method of treating tumor-bearing patients with human plasma hyaluronidase
US5891467A (en) 1997-01-31 1999-04-06 Depotech Corporation Method for utilizing neutral lipids to modify in vivo release from multivesicular liposomes
FR2763958A1 (fr) 1997-05-29 1998-12-04 Transgene Sa Produit de combinaison associant un acide nucleique a une substance desorganisant la matrice extracellulaire pour la therapie genique
US6306432B1 (en) * 1997-09-08 2001-10-23 Chiron Corporation High and low load formulations of IGF-I in multivesicular liposomes
US6106858A (en) 1997-09-08 2000-08-22 Skyepharma, Inc. Modulation of drug loading in multivescular liposomes
PT1014946E (pt) 1997-09-18 2010-07-06 Pacira Pharmaceuticals Inc COMPOSIÎES ANESTéSICAS LIPOSSOMAIS DE LIBERTAÆO SUSTENTADA
EP1028629A4 (en) 1997-11-05 2003-06-04 Biozone Lab Inc IMPROVED FOOD PREPARATION FOR INFANTS CONTAINING NUTRIENTS AND ACTIVE SUBSTANCES ENCLOSED IN LIPOSOMES
JP4575592B2 (ja) * 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド 多小胞リポソームの製造
JP4740455B2 (ja) 1998-08-12 2011-08-03 イーサム リサーチ ディベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム 硫酸アンモニウム勾配を使用して調製されるリポソーム性ブピバカイン組成物
US20020114829A1 (en) 1998-12-18 2002-08-22 Hayat Onyuksel Materials and methods for making improved liposome compositions
US20020009466A1 (en) 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US20020035107A1 (en) 2000-06-20 2002-03-21 Stefan Henke Highly concentrated stable meloxicam solutions
ATE444735T1 (de) 2001-03-21 2009-10-15 Madash Llc Thermisch reversible wasser-in-öl-in-wasser- emulsionen
US20020169102A1 (en) 2001-04-03 2002-11-14 Frey William H. Intranasal delivery of agents for regulating development of implanted cells in the CNS
US6709663B2 (en) * 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US20030235610A1 (en) 2002-06-21 2003-12-25 Piedmont Pharmaceuticals, Llc Liposomes containing biologically active compounds
US7485670B2 (en) 2002-08-02 2009-02-03 Cambridge Polymer Group, Inc. Systems and methods for controlling and forming polymer gels
US7473432B2 (en) * 2002-10-11 2009-01-06 Idea Ag NSAID formulations, based on highly adaptable aggregates, for improved transport through barriers and topical drug delivery
US20040224010A1 (en) * 2002-11-15 2004-11-11 Optime Therapeutics, Inc. Ophthalmic liposome compositions and uses thereof
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
CN102943067B (zh) 2003-03-05 2016-06-22 海洋酶公司 可溶性透明质酸酶糖蛋白(sHASEGP)、制备它们的方法、它们的用途和包含它们的药物组合物
US20070009583A1 (en) 2003-10-10 2007-01-11 Qvist Michael H Dressing
US20050268425A1 (en) 2004-04-20 2005-12-08 Clemons William E Sr Surface cleaner
US8129359B2 (en) 2004-06-04 2012-03-06 Ethicon, Inc. Composition and method for treating post-surgical pain
ES2490595T3 (es) 2005-02-17 2014-09-04 Abbott Laboratories Administración transmucosal de composiciones de fármacos para tratar y prevenir trastornos en animales
EP2248578B1 (en) 2005-03-04 2012-06-06 President and Fellows of Harvard College Method for forming multiple emulsions
US20070009434A1 (en) 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
WO2007049278A2 (en) 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparing liposomes and uses thereof
US8097646B2 (en) 2005-11-07 2012-01-17 Alpharx, Inc. Ophthalmic preparation containing menthyl ester of indomethacin
AU2007230716B2 (en) 2006-03-28 2012-05-03 Javelin Pharmaceuticals, Inc. Formulations of low dose diclofenac and beta-cyclodextrin
WO2007134819A1 (en) 2006-05-18 2007-11-29 Medigene Ag Cationic liposomal preparations for the treatment of rheumatoid arthritis
WO2008030818A2 (en) 2006-09-05 2008-03-13 Mebiopharm Co., Ltd. Novel liposome compositions
US20080075807A1 (en) 2006-09-22 2008-03-27 Baldwin Cheryl J Methods Of Fortifying Foods With Vitamin D And Food Products Thereof
DE602006018467D1 (de) * 2006-09-28 2011-01-05 Losan Pharma Gmbh Schnell lösliche Formulierung von nichtsteroidalen Antiphlogistika
EP2527345B1 (en) 2006-10-16 2015-12-16 Thesan Pharmaceuticals, Inc. Therapeutic pyrazolyl thienopyridines
US8268347B1 (en) 2006-10-24 2012-09-18 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
US8071127B2 (en) 2006-10-24 2011-12-06 Aradigm Corporation Dual action, inhaled formulations providing both an immediate and sustained release profile
WO2008073317A2 (en) 2006-12-08 2008-06-19 Musc Foundation For Research Development Cytarabine for treatment of glioma
EP1932516A1 (en) * 2006-12-11 2008-06-18 Universiteit Utrecht Holding B.V. Anti-inflammatory compounds containing compositions for treatment of cancer
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US8062663B2 (en) 2008-05-23 2011-11-22 National Health Research Instittues Methods and compostions for enhancing transdermal drug delivery
US8431692B2 (en) 2008-06-06 2013-04-30 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
US20110111044A1 (en) * 2008-07-31 2011-05-12 Enzon Pharmaceuticals, Inc. Nanoparticle compositions for nucleic acids delivery system
US8361935B2 (en) * 2008-08-29 2013-01-29 Schlumberger Technology Corporation Metal free crosslinking of galactomannan
CN102405286A (zh) * 2008-09-22 2012-04-04 阿克赛医药公司 减小大小的自递送RNAi化合物
CN101744764A (zh) * 2008-12-09 2010-06-23 上海医药工业研究院 一种空白和含盐酸拓扑替康的多囊脂质体及其制备方法
US20120027842A1 (en) 2008-12-23 2012-02-02 Amira Pharmaceuticals, Inc. Topical formulations of flap inhibitors for administration to an eye
US9968583B2 (en) 2009-03-30 2018-05-15 Eisai R & D Management Co., Ltd. Method of manufacture of liposome composition
US20110250264A1 (en) 2010-04-09 2011-10-13 Pacira Pharmaceuticals, Inc. Method for formulating large diameter synthetic membrane vesicles
WO2012058483A1 (en) 2010-10-28 2012-05-03 Pacira Pharmaceuticals, Inc. A sustained release formulation of a non-steroidal anti-inflammatory drug
HUE062466T2 (hu) * 2012-07-05 2023-11-28 Taiwan Liposome Co Ltd Eljárások arthritis kezelésére
CA2843943A1 (en) 2014-02-20 2014-05-28 Pankaj Modi Oral formulations of chemotherapeutic agents
US10137325B2 (en) * 2014-03-24 2018-11-27 Shantha Sarangapani System and method for deactivation and disposal of a pharmaceutical dosage form
JP6584146B2 (ja) 2015-05-27 2019-10-02 キヤノン株式会社 プリント装置

Also Published As

Publication number Publication date
US20130189348A1 (en) 2013-07-25
ES2770575T3 (es) 2020-07-02
JP2016040332A (ja) 2016-03-24
US10617642B2 (en) 2020-04-14
US20120114740A1 (en) 2012-05-10
US10123974B2 (en) 2018-11-13
US10729651B2 (en) 2020-08-04
US20130209548A1 (en) 2013-08-15
IL225881A0 (en) 2013-06-27
CN103260702B (zh) 2018-07-27
JP2013540824A (ja) 2013-11-07
US20130183374A1 (en) 2013-07-18
EP2632553A4 (en) 2016-07-20
JP6305973B2 (ja) 2018-04-04
EP2632553A1 (en) 2013-09-04
EP2632553B1 (en) 2020-01-01
US10610486B2 (en) 2020-04-07
JP6194248B2 (ja) 2017-09-06
WO2012058483A1 (en) 2012-05-03
US20130189350A1 (en) 2013-07-25
JP2018065877A (ja) 2018-04-26
US9974744B2 (en) 2018-05-22
US10675245B2 (en) 2020-06-09
CN103260702A (zh) 2013-08-21
US20130209547A1 (en) 2013-08-15

Similar Documents

Publication Publication Date Title
IL225881A0 (en) Delayed release formulation of a non-steroidal anti-inflammatory drug
PL2524692T3 (pl) Przeciwzapalny, przeciwbólowy plaster adhezyjny do zewnętrznego stosowania
ZA201306237B (en) Solid forms of a pharmaceutically active substance
HUE046628T2 (hu) Késleltetett felszabadulású gyógyszerkészítmény
IL222919A0 (en) Alcohol - resistant oral pharmaceutical form
EP2654638A4 (en) COMPOSITION FOR TRANSDERMAL ADMINISTRATION OF NON-STEROIDAL ANTI-INFLAMMATORY DRUG
EP2560484A4 (en) PHARMACEUTICAL COMPOSITION FROM NANOPARTICLES
BR112013013571A2 (pt) comprimido para a desintegração oral
SMT202000229T1 (it) Nuova forma di somministrazione di racecadotril
IT1401142B1 (it) Procedimento per la preparazione di compresse a rilascio controllato comprendenti melatonina
ZA201209038B (en) Adhesive slow-release formulations for the local administration of curcumin
GB201120908D0 (en) Patch containing non-steroidal anti-inflammatory drug
AP2014007760A0 (en) Stabilized pharmaceutical formulations of a potentHCV inhibitor
GB201001203D0 (en) Use of pharmaceutically active compounds
SMT202100289T1 (it) Pasta comprendente il farmaco antinfiammatorio non steroideo meloxicam
BR112013014963A2 (pt) comprimido farmacêutico de liberação controlada para administração oral
GB201009603D0 (en) Anti-inflammatory agent
FI20100072A0 (fi) Uudenlainen formulaatio
GB201001335D0 (en) Drug release formulations
GB201006090D0 (en) New target for anti-inflammatory drugs
HUP1000429A2 (en) Basic salts of a pharmaceutical active ingredient
GB201111387D0 (en) Prodrugs of pharmacologically active phenolic drug metabolites and uses thereof
PL390788A1 (pl) Betulina do zastosowania jako lek na choroby wątroby
HK1190074A (en) Sustained release paracetamol formulations
GB201016615D0 (en) Drug release composition

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed